

(43) International Publication Date
26 September 2013 (26.09.2013)

(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 35/00 (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2013/032575

(22) International Filing Date:

15 March 2013 (15.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/614,274 22 March 2012 (22.03.2012) US

(71) Applicants: GENOSCO [US/US]; 12801 Busch Place, Santa Fe Springs, CA 90670 (US). OSCOTEC, INC. [KR/KR]; 9th Floor, Tower A, Korea Bio Park 694-1, Sampyeong-dong, Bundang-gu, Seongnam, Gyeonggi-do, Republic of Korea 463-400 (KR).

(72) Inventors: KIM, Hong, Woo; 112 5th Street, Cambridge, MA 02141 (US). LEE, Hee, Kyu; 379-1401 Samik Sowol Apt. Ogeum-dong, Gunpo, Gyeonggi-do 435-756 (KP).


SONG, Ho-juhn; 141 Argilla Road, Andover, MA 01810 (US). LEE, Jaekyoo; 19 Elm Street, North Andover, MA 01845 (US). KOH, Jong, Sung; #404 Hansol Apt., Wonjong 1 Dong 300, Ojung-ku, Buchun, Gyeonggi-do 421-200 (KP). KIM, Youngsam; 99, Samseon-dong 5-ga, Seongbuk-gu, Seoul 136-045 (KP). KIM, Jung-ho; #707-501 Hyosung Apt., Imaedong, Bundang-gu, Seongnam, Gyeonggi-do 463-737 (KP). KIM, Se, Won; #611-702 Byuksan Apt., Yatap-dong, Bundang-gu, Seongnam, Gyeonggi-do 463-927 (KP). LEE, In, Yong; 23 Hill Road, Belmont, MA 02478 (US).

(74) Agents: KIM, Kongsik et al.; Edwards Wildman Palmer LLP, P.o. Box 55874, Boston, MA 02205 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,

[Continued on next page]

(54) Title: SUBSTITUTED PYRIDOPYRIMIDINE COMPOUNDS AND THEIR USE AS FLT3 INHIBITORS



(57) Abstract: Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).



RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

Published:

- with international search report (*Art. 21(3)*)
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (*Rule 48.2(h)*)